An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion (An efficacy tr)
The goal of this study is to test the efficacy of the Toolkit for Optimal Recovery after Concussion (TOR-C), a brief live-video mind-body program. aiming to prevent chronic concussion symptoms and optimize recovery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Mass General Brigham
-
Contact:
- Jonathan Greenberg
- Phone Number: 617-643-9402
- Email: MGHConcusionToolkit@partners.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Sustained a concussion 3-10 weeks earlier
- At least mild anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)
- Age 18-35
- English fluency and literacy
- Ability and willingness to participate in study procedures, assessments, and intervention
- Access to a smartphone or computer with internet access
- Cleared for participation by clinic/study staff
Exclusion Criteria:
- Participation in mind-body or CBT treatment in the past 3 months
- Concussion in the past 2 years that resulted in symptoms lasting 3 months or more / current or previous complicated or moderate/severe TBI
- Practice of mindfulness techniques > 45 minutes/week in the past 3 months
- Change in psychotropic medications (e.g., antidepressant, anxiolytics) in the past 6 weeks
- Uncontrolled bipolar disorder, psychosis, active substance dependence, self reported current active suicidal ideation with plan and/or intent
- Pregnancy
- Serious comorbidity expected to worsen in the next 6 months
- Secondary gains that may bias motivation (e.g., pending disability claim)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Toolkit for Optimal Recovery after Concussion (TOR-C)
A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills. |
TOR-C is a brief behavioral mind-body program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It targets anxiety and fear-avoidance factors to prevent chronic concussion symptoms, combining mind-body skills (e.g., mindfulness, deep breathing, acceptance), light cognitive-behavioral skills, skills for gradual return to activity, and concussion psychoeducation. |
|
Active Comparator: Health Enhancement after Concussion (HE-C)
A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion |
HE-C is an attention-matched active control program delivered remotely via live video over four weekly 45-minute sessions, with approximately 10 minutes of daily home practice. It provides general health education after concussion (e.g., sleep, nutrition, physical activity) without the specific skills included in TOR-C. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post-Concussion Symptom Scale (PCSS)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Generalized Anxiety Disorder scale (GAD-7)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of anxiety symptoms. (Also used at screening, where a score ≥5 is required for eligibility.) |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the severity of depression symptoms. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Fear Avoidance Behavior after Traumatic Brain Injury (FAB-TBI)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures fear-avoidance behavior, i.e., avoiding activities out of fear they will worsen symptoms. A core mechanism in the fear-avoidance model. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Symptom Catastrophizing Scale
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to catastrophize concussion symptoms (magnifying, ruminating on, or feeling helpless about them). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures mindfulness, i.e., present-moment awareness and acceptance of thoughts and feelings. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Behavioral Response to Illness Questionnaire (BRIQ): Limiting behavior subscale
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Measures the tendency to limit or avoid various activities in response to medical conditions |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures sleep quality over the past month. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
PROMIS Cognitive Function
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
An exploratory outcome which measures self-reported cognitive function (e.g., perceived problems with memory, attention, and thinking). |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
|
WHO Disability Assessment Schedule (WHODAS 2.0; 12-item version)
Time Frame: Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
It is 12-item measure of health-related functioning and disability across daily activities (e.g., cognition, mobility, self-care, social participation) over the past 30 days, with higher scores indicating greater disability. |
Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Greenberg J, Singh T, Iverson GL, Silverberg ND, Macklin EA, Parker RA, Giacino JT, Yeh GY, Vranceanu AM. A Live Video Mind-Body Treatment to Prevent Persistent Symptoms Following Mild Traumatic Brain Injury: Protocol for a Mixed Methods Study. JMIR Res Protoc. 2021 Jan 14;10(1):e25746. doi: 10.2196/25746.
- Greenberg J, Levey NS, Becker M, Yeh GY, Giacino JT, Iverson G, Silverberg ND, Parker RA, Vranceanu AM. Feasibility Randomized Controlled Trial of the Toolkit for Optimal Recovery After Concussion: A Live Video Program to Prevent Persistent Concussion Symptoms in Young Adults With Anxiety. Arch Phys Med Rehabil. 2025 Apr;106(4):527-536. doi: 10.1016/j.apmr.2024.10.011. Epub 2024 Nov 5.
- Becker ME, Stratton Levey N, Yeh GY, Giacino J, Iverson G, Silverberg N, Parker RA, McKinnon E, Siravo C, Shah P, Vranceanu AM, Greenberg J. Preliminary Feasibility of a Novel Mind-Body Program to Prevent Persistent Concussion Symptoms Among Young Adults With Anxiety: Nonrandomized Open Pilot Study. JMIR Form Res. 2024 Nov 8;8:e64540. doi: 10.2196/64540.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Injuries, Traumatic
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Wounds and Injuries
- Pathologic Processes
- Craniocerebral Trauma
- Trauma, Nervous System
- Head Injuries, Closed
- Wounds, Nonpenetrating
- Brain Injuries
- Pathological Conditions, Signs and Symptoms
- Anxiety Disorders
- Disease
- Brain Concussion
- Post-Concussion Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 2026P002591
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
We plan to share our study protocol, analysis plan, data dictionary, and de-identified data from all measures described under "outcome measures"
IPD Sharing Time Frame
Data from this study will be deposited into the Vivli database no later than one year of the completion of the funded project period
IPD Sharing Access Criteria
Interested parties can create an account in the Vivli Database and submit a request to access study data
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.